NME Approval Decline Likely To Continue In 2002: Only Two Filed This Year

FDA has received only two NDAs for new molecular entities so far in 2002, Office of New Drugs Director John Jenkins, MD, told UBS Warburg's specialty pharma conference in New York City June 6